Bioconvergence Revolution: Challenges and Opportunities in Research Productivity

Dr. Nina Siragusa holds the position of Strategy Business Lead at Merck Healthcare KGaA. Trained as a scientist with a doctorate in biology, Dr. Siragusa has dedicated her academic career to the flourishing field of bioconvergence, exploring a diverse array of topics. Her extensive research background encompasses fungal biology, delving into areas such as natural product research, molecular biology, and advanced sequencing and big data analysis across prestigious institutions in Europe and Yale University in the United States.

In 2016, Dr. Siragusa transitioned to Merck KGaA, where she assumed the role of Innovation Expert. In this capacity, she spearheaded the biotechnology segment of a pioneering synthetic biology project, once again synergizing digital technology and engineering within the framework of bioconvergence. Prior to her current role in the Healthcare Business unit, she was appointed Chief of Staff to Merck's Chief Science and Technology Officer, Laura Matz. During this period, Dr. Siragusa played a pivotal role in advancing the bioconvergence mega-trend, further solidifying her reputation as a leader in the field.

André T. Nemat is founder and Managing Partner of the Institute for Digital Transformation in Healthcare at Witten/Herdecke University, Germany. As a surgeon by training with an engineering background, he is an expert in the field of thoracic surgery. With a PhD from the University of Duesseldorf Germany, he has over 15 years of experience as chief physician and director of specialized lung-clinics.

Currently he acts as Executive Medical Director of the VKh.NRW. The "Virtual Hospital" is anchored in the Ministry of Health of the State of North Rhine-Westphalia and serves to transform the healthcare system by implementing digital innovations for comprehensive care. As a Boardmember of the International Data Spaces Association he focuses intensively on the added value of data-based innovation while preserving data sovereignty, on human digital twins in medicine and on digital ethics.

Dr. Nina Siragusa 擔任 Merck Healthcare KGaA 的策略業務負責人。她擁有生物學博士學位，並以科學家的身份接受訓練，致力於生物融合這一蓬勃發展的領域，探索多樣的主題。她的廣泛研究背景涵蓋真菌生物學，深入研究自然產物、分子生物學以及在歐洲和美國耶魯大學的先進測序和大數據分析等領域。

在 2016 年，Dr. Siragusa 轉職至 Merck KGaA，擔任創新專家。在此角色中，她領導了一個開創性的合成生物學項目的生物技術部分，再次將數位技術和工程整合於生物融合的框架內。在目前的醫療業務單位之前，她曾擔任 Merck 首席科學與技術官 Laura Matz 的幕僚長。在此期間，Dr. Siragusa 在推進生物融合的重大趨勢中發揮了關鍵作用，進一步鞏固了她在該領域的領導地位。

André T. Nemat 是德國維滕/赫爾德克大學數位轉型醫療研究所的創辦人及管理合夥人。作為一名受過外科訓練的醫生，並擁有工程背景，他是胸腔外科領域的專家。他擁有德國杜塞爾多夫大學的博士學位，並在專科肺科診所擔任首席醫生和主任超過 15 年。

目前，他擔任 VKh.NRW 的執行醫療主任。這個「虛擬醫院」隸屬於北萊茵-威斯特法倫州衛生部，旨在通過實施數位創新來轉型醫療系統，以提供全面的護理服務。作為國際數據空間協會的董事會成員，他專注於在保護數據主權的同時，數據驅動創新的附加價值，以及醫學中的人類數位雙胞胎和數位倫理。